Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type) @3 t8 b2 s9 _9 ^
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
$ t9 c1 i }7 |7 F- |1 t! o/ E' ]+ Author Affiliations
$ y* Y- x% d5 s+ P6 `" U Z% F+ w8 _3 ?1 F( r5 E7 k6 \; @1 B! u% a
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . a; J! A7 }# _ d( E
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) @- E; z$ E. F
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # p* i( q* p0 ~0 A z5 b/ |! `6 T
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
9 y: g8 s0 t# Z u+ M6 B6 y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
9 w, ~1 U7 W5 V% c- T# f/ C7 `; H3 ]6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
U5 c5 E& \5 A# N5 B# b7Kinki University School of Medicine, Osaka 589-8511, Japan
" |3 F3 p# ^* b5 m8Izumi Municipal Hospital, Osaka 594-0071, Japan : K" Z# }: S" v3 n5 o2 k$ i1 M
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 3 Q$ |5 w3 a* I9 P! G
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 3 n Z, p$ l; L0 Z$ w& t7 O
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 9 l! s% h( @) P3 c! P
+ t( U, d, H0 _$ O' s
|